HC Wainwright Reiterates Buy Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a report published on Thursday, Benzinga reports. The firm currently has a $14.00 price target on the stock.

Evaxion Biotech A/S Trading Up 2.0 %

Shares of Evaxion Biotech A/S stock opened at $3.12 on Thursday. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The company has a fifty day simple moving average of $3.00 and a 200-day simple moving average of $3.31. The stock has a market cap of $17.41 million, a price-to-earnings ratio of -0.72 and a beta of -0.27. Evaxion Biotech A/S has a 12-month low of $2.26 and a 12-month high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.14). The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.10 million. During the same period in the previous year, the company earned ($2.10) EPS. On average, equities analysts forecast that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Invst LLC acquired a new stake in shares of Evaxion Biotech A/S in the second quarter valued at approximately $156,000. Armistice Capital LLC increased its holdings in shares of Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after acquiring an additional 25,000 shares during the period. Finally, LM Advisors LLC purchased a new stake in Evaxion Biotech A/S in the 4th quarter valued at $231,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.